-
Product Insights
NewNet Present Value Model: IGM Biosciences Inc’s IGM-8444
Empower your strategies with our Net Present Value Model: IGM Biosciences Inc's IGM-8444 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Avibactam Tomilopil + Ceftibuten) in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Avibactam Tomilopil + Ceftibuten) in Urinary Tract Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Avibactam Tomilopil + Ceftibuten) in Urinary Tract Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Divarasib in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Divarasib in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Divarasib in Ovarian Cancer Drug Details: Divarasib (GDC-6036 (RG6330)) is under...
-
Product Insights
Chikungunya Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Chikungunya Fever - Drugs In Development, 2023’, provides an overview of the Chikungunya Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lymphocryptovirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Lymphocryptovirus Infections - Drugs In Development, 2023’, provides an overview of the Lymphocryptovirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lymphocryptovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Norovirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Norovirus Infections - Drugs In Development, 2023’, provides an overview of the Norovirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Norovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lyme Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Lyme Disease - Drugs In Development, 2023’, provides an overview of the Lyme Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lyme Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Net Present Value Model: Valneva SE’s VLA-1553
Empower your strategies with our Net Present Value Model: Valneva SE's VLA-1553 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VLA-1553 in Chikungunya Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VLA-1553 in Chikungunya Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VLA-1553 in Chikungunya Fever Drug Details: VLA-1553 is under development for the...